The HIV Protease and Therapies for AIDS

  • Bruce D. Korant
  • Christopher J. Rizzo
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 421)


New, potent therapies for HIV disease are available, based on synthetic inhibitors of the viral protease, an essential viral enzyme. The results in clinical trials have been impressive with most treated individuals benefiting in terms of reduced quantity of detectable virus, enhanced numbers of CD4 lymphocytes and improvements in quality and duration of life. However, there are some remaining negatives associated with the new drugs, including high cost, side effects and appearance of drug-resistant strains of HIV. Problems and future prospects for use of protease inhibitors and alternate approaches in AIDS are discussed.


Human Immunodeficiency Virus Proteinase Double Amino Acid Urea Inhibitor Viral Precursor Protein Current Status Figure 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Lalvani and J.S. Shastri. HIV Epidemic in India: Opportunity to learn from the past, Lancet 347 (1996)_ 1349–50.Google Scholar
  2. 2.
    M. Otto et al. In vitro isolation and identification of HIV variants with reduced sensitivity to a C-2 symmetrical inhibitor of HIV-1 protease, Proc. Natl. Acad. Sci. U.S.A. 90 (1993), 7543–7547.PubMedCrossRefGoogle Scholar
  3. 3.
    C.N. Hodge et al. Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and x-ray crystal structure of DMP 450, Chemistry and Biology 3 (1996), 301–314.PubMedCrossRefGoogle Scholar
  4. 4.
    A. Tomasselli and R. Heinrikson. Specificity of retroviral protease: An analysis of viral and non-viral protein substrates, Meth. Enzymol. 241, (1994), 279–301.Google Scholar
  5. 5.
    B. Korant, Z. Lu, P. Strack and C. Rizzo. HIV protease mutations leading to reduced inhibitor sensitivity, Adv. Exp. Med. Biol., 389 (1996), 241–246.PubMedCrossRefGoogle Scholar
  6. 6.
    H-G. Kraüsslich. Human immunodeficiency virus proteinase dimer as a component of the viral polyprotein prevents particle assembly and viral infectivity, Proc. Natl. Acad. Sci. USA 88, (1991), 3213–3217CrossRefGoogle Scholar
  7. 7.
    P. Strack et al. Apoptosis mediated by the HIV protease is preceded by cleavage of bel-2. Proc. Natl. Acad. Sci. USA 93, (1996), 9571–9576.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Bruce D. Korant
    • 1
  • Christopher J. Rizzo
    • 1
  1. 1.Virus Laboratory, Molecular Biology DepartmentDuPont Merck Pharmaceutical Co.WilmingtonUSA

Personalised recommendations